Literature DB >> 1834127

Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation.

R I Nicholson1, N Bouzubar, K J Walker, R McClelland, A R Dixon, J F Robertson, I O Ellis, R W Blamey.   

Abstract

The percentage of oestrogen receptor (ER) positive cells in a series of 118 breast cancers has been examined by immunohistochemistry in relation to patients' response to endocrine therapy. Positive and negative predictive values have been used to calculate appropriate cut-off points. The rate of response to treatment was significantly higher in women with receptor positive tumours, especially where the tumours contained more than 70% positive cells. Tumours that were apparently negative for ER expression rarely responded to endocrine therapy. The hormone sensitivity of ER positive breast cancer was also influenced by the rate of tumour cell proliferation, with tumours expressing high levels of Ki67 immunostaining rarely responding to therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834127     DOI: 10.1016/0277-5379(91)90145-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  16 in total

1.  Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.

Authors:  K Jirström; L Rydén; L Anagnostaki; B Nordenskjöld; O Stål; S Thorstenson; G Chebil; P-E Jönsson; M Fernö; G Landberg
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

2.  Steroid hormone receptors and their clinical significance in cancer.

Authors:  R I Nicholson; R A McClelland; J M Gee
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

3.  Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.

Authors:  S Rehman ; J Crow ; P A Revell
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

4.  Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.

Authors:  Pedram Heidari; Francis Deng; Shadi A Esfahani; Alicia K Leece; Timothy M Shoup; Neil Vasdev; Umar Mahmood
Journal:  Clin Cancer Res       Date:  2015-01-21       Impact factor: 12.531

5.  Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer.

Authors:  M A Fanelli; L M Vargas-Roig; F E Gago; O Tello; R Lucero De Angelis; D R Ciocca
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation.

Authors:  M Fernö; B Baldetorp; P O Bendahl; A Borg; S B Ewers; H Olsson; S Rydén; H Sigurdsson; D Killander
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

Authors:  R I Nicholson; R A McClelland; J M Gee; D L Manning; P Cannon; J F Robertson; I O Ellis; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

8.  The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins.

Authors:  C Schlüter; M Duchrow; C Wohlenberg; M H Becker; G Key; H D Flad; J Gerdes
Journal:  J Cell Biol       Date:  1993-11       Impact factor: 10.539

9.  Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy.

Authors:  R A McClelland; D L Manning; J M Gee; P Willsher; J F Robertson; I O Ellis; R W Blamey; R I Nicholson
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

10.  Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.

Authors:  D N Poller; D R Snead; E C Roberts; M Galea; J A Bell; A Gilmour; C W Elston; R W Blamey; I O Ellis
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.